Clinical features of acute ischemic stroke in moderately and severely ill patients with coronavirus disease 2019 (COVID-19)
Keywords:Acute ischemic stroke, COVID-19, clinical features, C-reactive protein, acute respiratory distress syndrome
Introduction and Aim: Although coronavirus disease 2019 (COVID-19) causes respiratory illness, it can even develop hypercoagulation and thrombotic complications. The main objective is to study the clinical features of acute ischemic stroke (AIS) with COVID-19 in moderately and severely ill patients.
Materials and Methods: A retrospective analysis of thirty-four (34) patients who were infected with COVID-19 and even diagnosed with AIS in September 2020 was assessed. The main clinical and neurological characteristics of stroke, the results of clinical, laboratory, biochemical, coagulation, lipid metabolism, and clinical examination studies of COVID-19 were assessed.
Results: The stroke severity, severity of brain damage, and degree of disability were reported more in the severely ill patients than in the moderately ill patients (p < 0.001, p = 0.002, and p = 0.7). Data from clinical-laboratory and biochemical parameters in moderately and severely ill patients showed that a more significant parameters are C-reactive protein (0.93 ± 0.03) and (5.79 ± 0.1); D-dimer (0.39 ± 0.11) and (0.76 ± 0.14); leukocytes (4.2 ± 1.69) and (3.6 ± 1.32), respectively (p < 0.001) and slightly altered values for fasting blood glucose levels (8.61 ± 2.41) and (7.21 ± 3.15). After clinical and pathomorphological analysis, acute respiratory distress syndrome signs were observed only in severely ill patients in 14 (41.1%).
Conclusion: Among all the parameters characterizing clinical-laboratory and biochemical differences, inflammatory and infectious markers, and fasting glucose were higher. In moderately and severely ill patients with AIS and COVID-19 has a significantly favorable outcome with a longer hospital stay.
GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017; 16(11): 877-897.
Westendorp, W. F., Vermeij, J. D., Zock, E., Hooijenga, I. J., Kruyt, N. D., Bosboom, H. J., et al., The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. Lancet. 2015; 385(9977): 1519-1526.
Bustamante, A., García-Berrocoso, T., Rodriguez, N., Llombart, V., Ribó, M., Molina, C., et al., Ischemic stroke outcome: A review of the influence of post-stroke complications within the different scenarios of stroke care. Eur J Intern Med. 2016; 29:9-21.
Zhang, Y., Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., et al., Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020; 382(17): e38.
Klok, F. A., Kruip, M., van der Meer, N., Arbous, M. S., Gommers, D., Kant, K. M., et al., Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191: 145-147.
Goyal, P., Choi, J. J., Pinheiro, L. C., Schenck, E. J., Chen, R., Jabri, A., et al., Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020; 382(24): 2372-2374.
Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., et al., Association of cardiac injury with mortality in hospitalized patients with covid-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-810.
Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., et al., Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-818.
Merkler, A. E., Parikh, N. S., Mir, S., Gupta, A., Kamel, H., Lin, E., et al., Risk of Ischemic Stroke in Patients with Coronavirus Disease 2019 (COVID-19) vs Patients with Influenza. JAMA Neurol. 2020;77(11):1-7.
Li, Y. C., Bai, W. Z., Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92(6):552-555.
Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q., et al., Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 683-690.
Government of Kyrgyz Republic. Ministry of Health of the Kyrgyz Republic; 2020. Available from: http://med.kg/images/koronavirus/prikaz_219_05042020.pdf. [Last accessed on 2020 Oct 30].
Emiru, T., Chaudhry, S. A., Qureshi, A. I. A survey of preprocedural intubation practices for endovascular treatment of acute ischemic stroke. J Vasc Interv Neurol. 2014;7(3):30-33.
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., et al., Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395(10234): 1417-1418.
Alsharidah, S., Ayed, M., Ameen, R. M., Alhuraish, F., Rouheldeen, N. A., Alshammari, F. R., et al., COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. Int J Infect Dis. 202; 103: 439-446.
Yang, X., Yu,Y., Xu, J., Shu, H., Xia, J., Liu, H., et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5): 475-481.
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.